

Date: 7th November, 2024

To,

The Manager,

Department of Corporate Services,

BSE Limited

P. J. Towers, Dalal Street, Fort, Mumbai – 400 001

Scrip Code: 533573

To,

The Manager,

Listing Department,

National Stock Exchange of India Ltd.

'Exchange Plaza', Bandra Kurla Complex,

Bandra (E), Mumbai - 400 051

NSE Symbol: APLLTD

Dear Sir/Madam,

Sub: Press Release on the Unaudited Financial Results for the quarter and half year ended 30th September, 2024.

With reference to the captioned subject, please find enclosed herewith Press Release on the Unaudited Financial Results for the quarter and half year ended 30th September, 2024.

We request you to kindly take the same on record.

Thanking you,

Yours faithfully,

For Alembic Pharmaceuticals Limited

Manisha Saraf Company Secretary

Encl.: A/a.



Press Release

Profit Before Tax up 25% to Rs. 168 Crores for the Quarter

Vadodara, November 7th, 2024

Alembic Pharmaceuticals Limited reported its consolidated financial results for the second quarter ended 30th September, 2024.

Financial Highlights

- Net Sales increased by 3% to Rs.1648 Crores.
- EBITDA up 18% to Rs. 257 Crores
- EBITDA Margin at 15.6% of Sales
- Net Profit up 12% to Rs.153 Crores.

Mr. Shaunak Amin, MD, Alembic Pharmaceuticals Limited said "India's Branded Business continues to enhance execution capabilities in both quality and scale, with the Specialty and Animal Health segments showing good growth. The USFDA successfully inspected our Oncology Formulation Facility (F-2) without any form 483 observations."

Operational Highlights

India Branded Business

- India Branded Business grew 6% to Rs. 609 Crores for the quarter.
- Recorded good growths in specialty therapies like 8% in Gynaecology, 11% in Cardiology, 18% in Anti Diabetic and 13% in Ophthalmology therapies.
- Animal Health business grew 20% for the quarter with basket of strong brands driving outperformance.
- 3 launches during the quarter. New launches continue to do well along with promising future launches across key segments.

International Business

- US Generics grew 5% to Rs. 467 Crores for the quarter.
- 8 Launches in the US market during the quarter.
- Ex-US International Formulations grew 18% to Rs. 298 Crores for the quarter.
- 9 ANDA approvals received during the quarter, 214 Cumulative ANDA approvals.



API Business

API business at Rs. 274 Crores for the quarter.

The summary of Total Revenue is as under:

(Rs in

Crores)

Particulars	Q2 FY25	Q2 FY24	% Change	H-1 FY25	H-1 FY24	% Change
Formulation						
India	609	577	6%	1181	1101	7%
USA	467	444	5%	928	834	11%
Ex- US	298	252	18%	568	518	10%
API	274	322	(15%)	532	628	(15%)
Total	1648	1595	3%	3210	3081	4%

About Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited, a vertically integrated research and development pharmaceutical company, has been at the forefront of healthcare since 1907. Headquartered in India, Alembic is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world. Alembic's state of the art research and manufacturing facilities are approved by regulatory authorities of many developed countries including the US FDA. Alembic is one of the leaders in branded generics in India. Alembic's brands, marketed through a field force of over 5200 are well recognized by doctors and patients.

Information about the company can be found at www.alembicpharmaceuticals.com; (reuters:ALEM.NS) (bloomberg:ALPM) (nse:APLLTD) (bse:533573)

For more information, contact:

Ajay Kumar Desai

Phone: +91 022-66953681

Email: ajay.desai@alembic.co.in